Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Abstract Text:

R J Woodman,R L Cysyk,I Kline,M Gang,J M Venditti,

The LD50 of intraperitoneally (ip) injected daunorubicin in nonleukemic mice (1.8 mg/kg, q4d times 3) can be increased several fold by the concomitant ip injection of ICRF-159. In addition, the survival of leukemic mice treated with daunorubicin and ICRF-159 on Days 1, 5, and 9 after ip inoculation of L1210 tumor cells was substantially greater than after treatment with either drug alone. This potentiation of survival with combination treatment usually occurred with doses of daunorubicin greater than the LD50 of daunorubicin alone. The LD50 of subcutaneously (sc) injected daunorubicin alone (14.0 mg/kg, q4d times 3) was not increased by concomitant ip treatment with ICRF-159. However, when leukemic mice were treated sc with daunorubicin and ip with ICRF-159 on Days 1, 5, and 9 after ip injection of L1210 leukemia cells, survival was greater than with treatment with either drug alone. The toxicity of ip injected adriamycin was not reduced by ICRF-159, but treatment of leukemic mice with this combination was more effective in prolonging survival than treatment with either drug alone. Combination treatment with daunorubicin plus ICRF-159 showed much less therapeutic enhancement against sc implanted L1210 leukemia than against the ip implanted tumor.

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Publishing Authors By Initials

RJ Woodman,RL Cysyk,I Kline,M Gang,JM Venditti,

For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

PUBMED ID PMID:

MEDLINE DATE: 1975 Jul-Aug

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Cancer chemotherapy reports. Part 1

VOLUME: 59

Page Numbers: 689-95

Journal Abbreviation:

ISSN: 0069-0112

DAY: 20

MONTH: 02

YEAR: 2008

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7607105

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Keywords Mesh Terms:

KEYWORDS: Time Factors

MESH TERMS: toxicity

Chemical & Substance for Abstract: Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Information

Substance Name: Doxorubicin

Registry Number: 23214-92-8

Grant and Affiliation Information for Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Chemother Rep

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Enhancement of the effectiveness of daunorubicin NSC-82151 or adriamycin NSC-123127 against early mouse L1210 leukemia with ICRF-159 NSC-129943 Related Publications

• A Dialysis Patient with Bacteremia Caused by a Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Carrying the Staphylococcal Chromosome Cassette (SCC) mec type V.
• A manual on quantitative drug evaluation in experimental tumor systems.
• A meta-analytic approach to ilioinguinal nerve excision or preservation during open inguinal hernia repair.
• A prospective screening program: current screening and its status.
• Adenoviral-mediated correction of methylmalonyl-CoA mutase deficiency in murine fibroblasts and human hepatocytes.
• Adenovirus-Mediated Gene Delivery Rescues a Neonatal Lethal Murine Model of mut(0) Methylmalonic Acidemia.
• Antileukemic action of reserpine.
• Changes in susceptibilities to teicoplanin, vancomycin and other antibiotics among Staphylococcus aureus isolates in a tertiary-care University hospital.
• Combination radiotherapy and chemotherapy for P388 lymphocytic leukemia in vivo.
• Combination therapy studies with L-asparaginase (NSC-109229) and other antitumor agents.
• Effectiveness of antileukemic agents in mice inoculated with a leukemia L1210 variant resistant to 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196).
• Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196).
• Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
• Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
• Immunity of mice surviving systemic leukaemia (L1210) to antifolic resistant variants of the disease.
• In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
• Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle.
• Multidrug-Resistant Acinetobacter baumannii Outbreak in an Intensive Care Unit.
• Observations on a leukemic cell variant in mice.
• Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
• Post-endoscopic polypectomy delayed bleeding concomitant with an abdominoperineal resection: a case report.
• Prediction of the long-term creep behaviour of hydroxyapatite-filled polyethylmethacrylate bone cements.
• Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.
• Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
• The accumulation of reproductive barriers during speciation: postmating barriers in two behaviorally isolated species of darters (Percidae: Etheostoma).
• The efficacy and safety of maintenance ECT in geriatric patients.
• The new NCI screen and its implications for clinical evaluation.
• Upper and lower gastrointestinal diseases in liver transplant candidates.
• Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroe
• Working session report: in vivo-in vitro screening.